Race Oncology reports “enhancement” of cancer cell-killing capabilities

The Market Herald05-14

Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435582200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-14 07:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435582200","market":"us","top_or_hot":-1,"title":"Race Oncology reports “enhancement” of cancer cell-killing capabilities","media":"The Market Herald","content":"<div>\n<p>Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed ...</p>\n\n<a href=\"https://themarketonline.com.au/race-oncology-reports-enhancement-of-cancer-cell-killing-capabilities-2024-05-14/\">Source Link</a>\n\n</div>\n","source":"markerherald_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology reports “enhancement” of cancer cell-killing capabilities</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology reports “enhancement” of cancer cell-killing capabilities\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-14 07:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://themarketonline.com.au/race-oncology-reports-enhancement-of-cancer-cell-killing-capabilities-2024-05-14/><strong>The Market Herald</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed ...</p>\n\n<a href=\"https://themarketonline.com.au/race-oncology-reports-enhancement-of-cancer-cell-killing-capabilities-2024-05-14/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://themarketonline.com.au/race-oncology-reports-enhancement-of-cancer-cell-killing-capabilities-2024-05-14/","article_id":"2435582200","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435582200","pubTimestamp":1715644560,"sourceInfo":{"source_id":"markerherald_stock","name":"The Market Herald"},"weMediaInfo":null,"summary":"Race Oncology  had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial.That enhancement came from studies looking at a combination of bisantrene and decitabine – both chemotherapeutic drugs, used together, are more effective at killing cancerous cells across “a broad panel of 143 tumour cell lines.”Notably, it’s the combination of these drugs that’s proven to be more effective than either compound taken on its own. The cell lines tested came from over 20 different human tissue specimens.Of the 143 different cell lines, the aforementioned combination showed “enhanced” cancer cell-killing properties in 131 out of 143 samples – 92%.Meanwhile, 56% of cell lines “[showed] les than two-fold increases in activity for the combination, relative to bisantrene alone, and 36% showed up to 2-fold-improvements.”“While decitabine has proven its effectiveness i","collect":0,"end_time":0,"defaultTopTitle":"themarketonline.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","RAC.AU":"RACE ONCOLOGY LTD","BK7508":"医药生物股"},"translate_title":"种族肿瘤学报道癌细胞杀伤能力的“增强”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Race Oncology (ASX:RAC) had caught the eyes of HotCopper users pre-market on Tuesday as the company reported enhancement of its ability to kill cancer cells – to be further explored in a proposed Phase I/II leukaemia trial. \nThat enhancement came from studies looking at a combination of bisantrene and decitabine – both chemotherapeutic drugs, used together, are more effective at killing cancerous cells across “a broad panel of 143 tumour cell lines.”\nNotably, it’s the combination of these drugs that’s proven to be more effective than either compound taken on its own. The cell lines tested came from over 20 different human tissue specimens.\nOf the 143 different cell lines, the aforementioned combination showed “enhanced” cancer cell-killing properties in 131 out of 143 samples – 92%. \nMeanwhile, 56% of cell lines “[showed] les than two-fold increases in activity for the combination, relative to bisantrene alone, and 36% showed up to 2-fold-improvements.” \nA cohort of cell lines reflecting 8% of the overall set tested showed no improvement for the combination. \nThe in-house research on tissue samples to date, Race said, is applicable to solid tumours including cancers of the lung, prostate, pancreas, breast, head, and neck.\nManagement noted on Tuesday that decitabine is a well known chemo drug typically used in blood cancers, in combination with bisantrene, the haematological drug could be more widely used in the treatment of solid tumours as well as blood cancer.\n“While decitabine has proven its effectiveness in haematological cancers, it has not demonstrated clinical utility in solid tumours, like lung or breast cancer,” Race chief Dr. Daniel Tillett said.\n“This new body of work is highly supportive of the results from the University of Newcastle in preclinical AML models using a combination of bisantrene and decitabine.”\nRAC closed at $1.55 on Monday.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.23.1","shortVersion":"4.23.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435582200"}